Pioglitazone Ameliorates Hippocampal Neurodegeneration, Disturbances in Glucose Metabolism and AKT/mTOR Signaling Pathways in Pentyelenetetrazole-Kindled Mice

• Published in: Pharmaceuticals (Basel, Switzerland) Switzerland), 2022-09, Vol.15 (9), p.1113
• Main Authors: El-Megiri, Nada, Mostafa, Yasser M, Ahmed, Amal, Mehanna, Eman T, El-Azab, Mona F, Alshehri, Fatma, Alahdal, Hadil, El-Sayed, Norhan M
• Format: Article
• Language: English
• Subjects: Blood vessels; Brain research; Cellular signal transduction; Convulsions & seizures; Degeneration; Drug dosages; Drug therapy; Epilepsy; Glucose; Glucose metabolism; Health aspects; Hippocampus (Brain); Kinases; m-TOR; Metabolism; nerve growth factor; Nervous system; Neuroprotective agents; pentylenetetrazole; Pharmacology, Experimental; pioglitazone; Proteins; Seizures (Medicine); Testing
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph15091113

Disturbance of glucose metabolism, nerve growth factor (NGF) and m-TOR signaling have been associated with the pathophysiology of epilepsy. Pioglitazone (PGZ) is an anti-diabetic drug that shows a protective effect in neurodegenerative diseases including epilepsy; however, its exact mechanism is not fully elucidated. The present study aimed to investigate the potential neuroprotective effect of PGZ in pentylenetetrazole (PTZ) kindled seizure in mice. Swiss male albino mice were randomly distributed into four groups, each having six mice. Group 1 was considered the control. Epilepsy was induced by PTZ (35 mg/kg i.p.) thrice a week for a total of 15 injections in all other groups. Group 2 was considered the untreated PTZ group while Group 3 and Group 4 were treated by PGZ prior to PTZ injection at two dose levels (5 and 10 mg/kg p.o., respectively). Seizure activity was evaluated after each PTZ injection according to the Fischer and Kittner scoring system. At the end of the experiment, animals were sacrificed under deep anesthesia and the hippocampus was isolated for analysis of glucose transporters by RT-PCR, nerve growth factor (NGF) by ELISA and mTOR by western blotting, in addition to histopathological investigation. The PTZ-treated group showed a significant rise in seizure score, NGF and m-TOR hyperactivation, along with histological abnormalities compared to the control group. Treatment with PGZ demonstrated a significant decrease in NGF, seizure score, m-TOR, GLUT-1 and GLUT-3 in comparison to the PTZ group. In addition, improvement of histological features was observed in both PGZ treated groups. These findings suggest that PGZ provides its neuroprotective effect through modulating m-TOR signaling, glucose metabolism and NGF levels.